2 terminated, 1 completed. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Terminated 2, Completed 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Acute-graft-versus-host Disease: new trials by email Literature Review of Acute-graft-versus-host Disease trials Research Report on Acute-graft-versus-host Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR) Itolizumab, EQ001 Placebo - Graft Versus Host Disease, GVHD | Phase 3 | Terminated | Equillium | 158 | 2022-04-29 | 2025-06-17 |
| Sitagliptin for Prevention of aGVHD After Alternative Donor Transplation Sitagliptin + Standard Prophylaxis, Standard Prophylaxis - Acute-graft-versus-host Disease, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 3 | Completed | The First Affiliated Hospital of Soochow University | 190 | 2021-12-22 | 2026-02-10 |
| The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant AAT, Placebo - Acute-graft-versus-host Disease | Phase 2 / Phase 3 | Terminated | CSL Behring | 222 | 2019-03-27 | 2026-09-09 |
Cyclosporine (1) · Respreeza (1) · Sitagliptin Phosphate (1) · alpha 1-Antitrypsin (1) · itolizumab (1)
CSL Behring (1) · Equillium (1) · The First Affiliated Hospital of Soochow University (1)
Australia (2) · Germany (2) · Italy (2) · South Korea (2) · Spain (2) · United States (2) · Belgium (1) · Canada (1) · China (1) · France (1) · Israel (1) · Japan (1) · New Zealand (1) · Portugal (1) · Turkey (Türkiye) (1)
2018 (1)